{"PubmedBookArticle": [], "PubmedArticle": [{"MedlineCitation": {"KeywordList": [], "SpaceFlightMission": [], "InvestigatorList": [], "OtherAbstract": [], "OtherID": [], "CitationSubset": ["IM"], "GeneralNote": [], "PMID": "31937840", "DateCompleted": {"Year": "2020", "Month": "11", "Day": "10"}, "DateRevised": {"Year": "2024", "Month": "07", "Day": "24"}, "Article": {"ArticleDate": [{"Year": "2020", "Month": "01", "Day": "14"}], "Language": ["eng"], "ELocationID": ["257", "10.1038/s41598-019-57199-9"], "Journal": {"ISSN": "2045-2322", "JournalIssue": {"Volume": "10", "Issue": "1", "PubDate": {"Year": "2020", "Month": "Jan", "Day": "14"}}, "Title": "Scientific reports", "ISOAbbreviation": "Sci Rep"}, "ArticleTitle": "Combined network pharmacology and virtual reverse pharmacology approaches for identification of potential targets to treat vascular dementia.", "Pagination": {"StartPage": "257", "MedlinePgn": "257"}, "Abstract": {"AbstractText": ["Dementia is a major cause of disability and dependency among older people. If the lives of people with dementia are to be improved, research and its translation into druggable target are crucial. Ancient systems of healthcare (Ayurveda, Siddha, Unani and Sowa-Rigpa) have been used from centuries for the treatment vascular diseases and dementia. This traditional knowledge can be transformed into novel targets through robust interplay of network pharmacology (NetP) with reverse pharmacology (RevP), without ignoring cutting edge biomedical data. This work demonstrates interaction between recent and traditional data, and aimed at selection of most promising targets for guiding wet lab validations. PROTEOME, DisGeNE, DISEASES and DrugBank databases were used for selection of genes associated with pathogenesis and treatment of vascular dementia (VaD). The selection of new potential drug targets was made by methods of NetP (DIAMOnD algorithm, enrichment analysis of KEGG pathways and biological processes of Gene Ontology) and manual expert analysis. The structures of 1976 phytomolecules from the 573 Indian medicinal plants traditionally used for the treatment of dementia and vascular diseases were used for computational estimation of their interactions with new predicted VaD-related drug targets by RevP approach based on PASS (Prediction of Activity Spectra for Substances) software. We found 147 known genes associated with vascular dementia based on the analysis of the databases with gene-disease associations. Six hundred novel targets were selected by NetP methods based on 147 gene associations. The analysis of the predicted interactions between 1976 phytomolecules and 600 NetP predicted targets leaded to the selection of 10 potential drug targets for the treatment of VaD. The translational value of these targets is discussed herewith. Twenty four drugs interacting with 10 selected targets were identified from DrugBank. These drugs have not been yet studied for the treatment of VaD and may be investigated in this field for their repositioning. The relation between inhibition of two selected targets (GSK-3, PTP1B) and the treatment of VaD was confirmed by the experimental studies on animals and reported separately in our recent publications."]}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Pirogov Russian National Research Medical University, Department of Bioinformatics, Moscow, 117997, Russia. alexey.lagunin@ibmc.msk.ru."}, {"Identifier": [], "Affiliation": "Institute of Biomedical Chemistry, Department of Bioinformatics, Moscow, 119121, Russia. alexey.lagunin@ibmc.msk.ru."}], "LastName": "Lagunin", "ForeName": "Alexey A", "Initials": "AA"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Pirogov Russian National Research Medical University, Department of Bioinformatics, Moscow, 117997, Russia."}, {"Identifier": [], "Affiliation": "Institute of Biomedical Chemistry, Department of Bioinformatics, Moscow, 119121, Russia."}], "LastName": "Ivanov", "ForeName": "Sergey M", "Initials": "SM"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Institute of Biomedical Chemistry, Department of Bioinformatics, Moscow, 119121, Russia."}], "LastName": "Gloriozova", "ForeName": "Tatyana A", "Initials": "TA"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Institute of Biomedical Chemistry, Department of Bioinformatics, Moscow, 119121, Russia."}], "LastName": "Pogodin", "ForeName": "Pavel V", "Initials": "PV"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Institute of Biomedical Chemistry, Department of Bioinformatics, Moscow, 119121, Russia."}], "LastName": "Filimonov", "ForeName": "Dmitry A", "Initials": "DA"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Punjabi University, Department of Pharmaceutical Sciences and Drug Research, Patiala, 147002, India."}], "LastName": "Kumar", "ForeName": "Sandeep", "Initials": "S"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Punjabi University, Department of Pharmaceutical Sciences and Drug Research, Patiala, 147002, India. goelrkpup@gmail.com."}], "LastName": "Goel", "ForeName": "Rajesh K", "Initials": "RK"}], "PublicationTypeList": ["Journal Article", "Research Support, Non-U.S. Gov't"]}, "MedlineJournalInfo": {"Country": "England", "MedlineTA": "Sci Rep", "NlmUniqueID": "101563288", "ISSNLinking": "2045-2322"}, "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Databases, Factual"}, {"QualifierName": ["drug therapy"], "DescriptorName": "Dementia, Vascular"}, {"QualifierName": ["methods"], "DescriptorName": "Drug Evaluation, Preclinical"}, {"QualifierName": [], "DescriptorName": "Molecular Targeted Therapy"}, {"QualifierName": [], "DescriptorName": "Pharmacology"}, {"QualifierName": [], "DescriptorName": "User-Computer Interface"}], "CoiStatement": "The authors declare no competing financial or non-financial interests."}, "PubmedData": {"ReferenceList": [{"ReferenceList": [], "Reference": [{"Citation": "Livingston G, et al. Dementia burden coming into focus. Lancet. 2017;390:2673\u20132734. doi: 10.1016/S0140-6736(17)31363-6.", "ArticleIdList": ["10.1016/S0140-6736(17)31363-6", "29256397"]}, {"Citation": "Thal DR, Grinberg LT, Attems J. Vascular dementia: different forms of vessel disorders contribute to the development of dementia in the elderly brain. Exp. Geronto. 2012;47:816\u2013824. doi: 10.1016/j.exger.2012.05.023.", "ArticleIdList": ["10.1016/j.exger.2012.05.023", "PMC3470831", "22705146"]}, {"Citation": "Budson, A. E. & Solomon, P. R. Chapter 6 \u2013 Vascular Dementia and Vascular Cognitive Impairment, in: Memory Loss, Alzheimer\u2019s Disease, and Dementia. In: A Practical Guide for Clinicians. 2nd ed. 80\u201389 (Elsevier, 2016)."}, {"Citation": "Gomazkov OA, Lagunin AA. Vascular Dementia: Molecular Targets of Neuroprotective Therapy. Biol. Bull. Rev. 2017;7:528\u2013536. doi: 10.1134/S2079086417060032.", "ArticleIdList": ["10.1134/S2079086417060032"]}, {"Citation": "Albert M, et al. Heart risks in middle age boost dementia risk later in life. Am. Stroke Assoc. Meet. Report, Session A. 2017;14:98."}, {"Citation": "Kling MA, Trojanowski JQ, Wolk DA, Lee VM, Arnold SE. Vascular disease and dementias: paradigm shifts to drive research in new directions. Alzheimers Dement. 2013;9:76\u201392. doi: 10.1016/j.jalz.2012.02.007.", "ArticleIdList": ["10.1016/j.jalz.2012.02.007", "PMC3640817", "23183137"]}, {"Citation": "Vidal M, Cusick ME, Barab\u00e1si A-L. Interactome Networks and Human Disease. Cell. 2011;144:986\u2013998. doi: 10.1016/j.cell.2011.02.016.", "ArticleIdList": ["10.1016/j.cell.2011.02.016", "PMC3102045", "21414488"]}, {"Citation": "Caldera M, Buphamalai P, M\u00fcller F, Menche J. Interactome-based approaches to human disease. Curr Opin. Syst. Biol. 2017;3:88\u201394."}, {"Citation": "Zhao J, Jiang P, Zhang W. Molecular networks for the study of TCM Pharmacology. Brief. Bioinform. 2010;11:417\u2013430. doi: 10.1093/bib/bbp063.", "ArticleIdList": ["10.1093/bib/bbp063", "20038567"]}, {"Citation": "Li Jian, Lu Cheng, Jiang Miao, Niu Xuyan, Guo Hongtao, Li Li, Bian Zhaoxiang, Lin Na, Lu Aiping. Traditional Chinese Medicine-Based Network Pharmacology Could Lead to New Multicompound Drug Discovery. Evidence-Based Complementary and Alternative Medicine. 2012;2012:1\u201311.", "ArticleIdList": ["PMC3541710", "23346189"]}, {"Citation": "Tao WY, et al. Network pharmacology-based prediction of the active ingredients and potential targets of Chinese herbal radix curcumae formula for application to cardiovascular disease. J. Ethnopharmacol. 2013;145:1\u201310. doi: 10.1016/j.jep.2012.09.051.", "ArticleIdList": ["10.1016/j.jep.2012.09.051", "23142198"]}, {"Citation": "Li S, Zhang B. Traditional Chinese medicine network pharmacology: theory, methodology and application. Chin. J. Nat. Med. 2013;11:110\u2013120. doi: 10.3724/SP.J.1009.2013.00110.", "ArticleIdList": ["10.3724/SP.J.1009.2013.00110", "23787177"]}, {"Citation": "Pi\u00f1ero J, et al. DisGeNET: a comprehensive platform integrating infor-mation on human disease-associated genes and variants. Nucleic Acids Res. 2017;45(D1):D833\u2013D839. doi: 10.1093/nar/gkw943.", "ArticleIdList": ["10.1093/nar/gkw943", "PMC5210640", "27924018"]}, {"Citation": "Liu CC, et al. DiseaseConnect: a comprehensive web server for mecha-nism-based disease-disease connections. Nucleic Acids Res. 2014;42(Web Server issue):W137\u2013W146. doi: 10.1093/nar/gku412.", "ArticleIdList": ["10.1093/nar/gku412", "PMC4086092", "24895436"]}, {"Citation": "Pletscher-Frankild S, Pallej\u00e0 A, Tsafou K, Binder JX, Jensen LJ. DISEASES: text mining and data integration of disease-gene associations. Methods. 2015;74:83\u201389. doi: 10.1016/j.ymeth.2014.11.020.", "ArticleIdList": ["10.1016/j.ymeth.2014.11.020", "25484339"]}, {"Citation": "Wishart DS, et al. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018;46(D1):D1074\u2013D1082. doi: 10.1093/nar/gkx1037.", "ArticleIdList": ["10.1093/nar/gkx1037", "PMC5753335", "29126136"]}, {"Citation": "Gaulton A, et al. The ChEMBL database in 2017. Nucleic Acids Res. 2017;45(D1):D945\u2013D954. doi: 10.1093/nar/gkw1074.", "ArticleIdList": ["10.1093/nar/gkw1074", "PMC5210557", "27899562"]}, {"Citation": "Wang Y, et al. PubChem BioAssay: 2017 update. Nucleic Acids Res. 2017;45(D1):D955\u2013D963. doi: 10.1093/nar/gkw1118.", "ArticleIdList": ["10.1093/nar/gkw1118", "PMC5210581", "27899599"]}, {"Citation": "Kanehisa M, Sato Y, Furumichi M, Morishima K, Tanabe M. New approach for understanding genome variations in KEGG. Nucleic Acids Res. 2019;47:D590\u2013D595. doi: 10.1093/nar/gky962.", "ArticleIdList": ["10.1093/nar/gky962", "PMC6324070", "30321428"]}, {"Citation": "The Gene Ontology Consortium The Gene Ontology Resource: 20 years and still GOing strong. Nucleic Acids Res. 2019;47(D1):D330\u2013D338. doi: 10.1093/nar/gky1055.", "ArticleIdList": ["10.1093/nar/gky1055", "PMC6323945", "30395331"]}, {"Citation": "Sherman BT, Lempicki RA. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res. 2009;37(1):1\u201313. doi: 10.1093/nar/gkn923.", "ArticleIdList": ["10.1093/nar/gkn923", "PMC2615629", "19033363"]}, {"Citation": "Ghiassian SD, Menche J, Barab\u00e1si AL. A DIseAse MOdule Detection (DIAMOnD) algorithm derived from a systematic analysis of connectivity patterns of disease proteins in the human interactome. PLoS Comput. Biol. 2015;11:e1004120. doi: 10.1371/journal.pcbi.1004120.", "ArticleIdList": ["10.1371/journal.pcbi.1004120", "PMC4390154", "25853560"]}, {"Citation": "Perfetto L, et al. SIGNOR: a database of causal relationships between biological entities. Nucleic Acids Res. 2016;44(D1):D548\u2013D554. doi: 10.1093/nar/gkv1048.", "ArticleIdList": ["10.1093/nar/gkv1048", "PMC4702784", "26467481"]}, {"Citation": "Poroikov VV, Filimonov DA, Borodina YV, Lagunin AA, Kos A. Robustness of biological activity spectra predicting by computer program PASS for non-congeneric sets of chemical compounds. J. Chem. Inf. Comput. Sci. 2000;40:1349\u20131355. doi: 10.1021/ci000383k.", "ArticleIdList": ["10.1021/ci000383k", "11128093"]}, {"Citation": "Subramanian A, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA. 2005;102:15545\u201315550. doi: 10.1073/pnas.0506580102.", "ArticleIdList": ["10.1073/pnas.0506580102", "PMC1239896", "16199517"]}, {"Citation": "Filimonov D, Poroikov V, Borodina Y, Gloriozova T. Chemical Similarity Assessment through Multilevel Neighborhoods of Atoms:\u2009 Definition and Comparison with the other descriptors. J. Chem. Inf. Comput. Sci. 1999;39:666\u2013670. doi: 10.1021/ci980335o.", "ArticleIdList": ["10.1021/ci980335o"]}, {"Citation": "Filimonov DA, et al. Prediction of the Biological Activity Spectra of Organic Compounds Using the PASS Online Web Resource. Chem. Heterocycl. Compd. 2014;50:444\u2013457. doi: 10.1007/s10593-014-1496-1.", "ArticleIdList": ["10.1007/s10593-014-1496-1"]}, {"Citation": "Lagunin A, Stepanchikova A, Filimonov D, Poroikov V. PASS: Prediction of Activity Spectra for Biologically Active Substances. Bioinformatics. 2000;16:747\u2013748. doi: 10.1093/bioinformatics/16.8.747.", "ArticleIdList": ["10.1093/bioinformatics/16.8.747", "11099264"]}, {"Citation": "Kringelum J, et al. ChemProt-3.0: a global chemical biology diseases mapping. Database (Oxford). 2016;2016:bav123. doi: 10.1093/database/bav123.", "ArticleIdList": ["10.1093/database/bav123", "PMC4752971", "26876982"]}, {"Citation": "Nickel J, et al. SuperPred: update on drug classification and target prediction. Nucleic Acids Res. 2014;42(Web Server issue):W26\u2013W31. doi: 10.1093/nar/gku477.", "ArticleIdList": ["10.1093/nar/gku477", "PMC4086135", "24878925"]}, {"Citation": "Keiser MJ, et al. Relating protein pharmacology by ligand chemistry. Nat. Biotechnol. 2007;25:197\u2013206. doi: 10.1038/nbt1284.", "ArticleIdList": ["10.1038/nbt1284", "17287757"]}, {"Citation": "Daina A, Michielin O, Zoete V. SwissTargetPrediction: updated data and new features for efficient prediction of protein targets of small molecules. Nucleic Acids Res. 2019;47(W1):W357\u2013W364. doi: 10.1093/nar/gkz382.", "ArticleIdList": ["10.1093/nar/gkz382", "PMC6602486", "31106366"]}, {"Citation": "Wang L, et al. TargetHunter: an in silico target identification tool for predicting therapeutic potential of small organic molecules based on chemogenomic database. AAPS J. 2013;15:395\u2013406. doi: 10.1208/s12248-012-9449-z.", "ArticleIdList": ["10.1208/s12248-012-9449-z", "PMC3675739", "23292636"]}, {"Citation": "Luo H, et al. DRAR-CPI: a server for identifying drug repositioning potential and adverse drug reactions via the chemical-protein interactome. Nucleic Acids Res. 2011;39(Web Server issue):W492\u2013W498. doi: 10.1093/nar/gkr299.", "ArticleIdList": ["10.1093/nar/gkr299", "PMC3125745", "21558322"]}, {"Citation": "Murtazalieva KA, Druzhilovskiy DS, Goel RK, Sastry GN, Poroikov VV. How good are publicly available web services that predict bioactivity profiles for drug repurposing? SAR. QSAR Env. Res. 2017;28:843\u2013862. doi: 10.1080/1062936X.2017.1399448.", "ArticleIdList": ["10.1080/1062936X.2017.1399448", "29183230"]}, {"Citation": "Lagunin A, Filimonov D, Poroikov V. Multi-Targeted Natural Products Evaluation Based on Biological Activity Prediction with PASS. Curr. Pharm. Des. 2010;16:1703\u20131717. doi: 10.2174/138161210791164063.", "ArticleIdList": ["10.2174/138161210791164063", "20222853"]}, {"Citation": "Lagunin AA, et al. Chemo- and bioinformatics resources for in silico drug discovery from medicinal plants beyond their traditional use: a critical review. Nat. Prod. Rep. 2014;31:1585\u20131611. doi: 10.1039/C4NP00068D.", "ArticleIdList": ["10.1039/C4NP00068D", "25051191"]}, {"Citation": "Su G, Morris JH, Demchak B, Bader GD. Biological network exploration with Cytoscape 3. Curr. Protoc. Bioinformatics. 2014;47(8):13.1\u201324. doi: 10.1002/0471250953.bi0813s47.", "ArticleIdList": ["10.1002/0471250953.bi0813s47", "PMC4174321", "25199793"]}, {"Citation": "Adamski MG, et al. Expression profile based gene clusters for ischemic stroke detection. Genomics. 2014;104:163\u2013169. doi: 10.1016/j.ygeno.2014.08.004.", "ArticleIdList": ["10.1016/j.ygeno.2014.08.004", "PMC4196244", "25135788"]}, {"Citation": "Minett T, et al. Microglial immunophenotype in dementia with Alzheimer\u2019s pathology. J. Neuroinflammation. 2016;13:135. doi: 10.1186/s12974-016-0601-z.", "ArticleIdList": ["10.1186/s12974-016-0601-z", "PMC4890505", "27256292"]}, {"Citation": "M\u00f6derscheim TA, et al. Prolactin is involved in glial responses following a focal injury to the juvenile rat brain. Neuroscience. 2007;145:963\u2013973. doi: 10.1016/j.neuroscience.2006.12.053.", "ArticleIdList": ["10.1016/j.neuroscience.2006.12.053", "17317019"]}, {"Citation": "Yu QS, et al. Anticholinesterase activity of compounds related to geneser-ine tautomers. N-Oxides and 1,2-oxazines. J. Med. Chem. 2002;45:3684\u20133691. doi: 10.1021/jm010491d.", "ArticleIdList": ["10.1021/jm010491d", "12166941"]}, {"Citation": "Yu QS, Atack JR, Rapoport SI, Brossi A. Synthesis and anticholinesterase activity of (\u2212)-N1-norphysostigmine, (\u2212)-eseramine, and other N(1)-substituted analogues of (\u2212)-physostigmine. J. Med. Chem. 1988;31:2297\u20132300. doi: 10.1021/jm00120a008.", "ArticleIdList": ["10.1021/jm00120a008", "3193422"]}, {"Citation": "Al-Lazikani, B. et al. The Molecular Basis of Predicting Druggability. In Chemical Biology: From Small Molecules to Systems Biology and Drug Design 1\u20133. (eds Wess, G, Schreiber, S. L. & Kapoor, T. M.) 804\u2013823 (Wiley-VCH, 2007)."}, {"Citation": "Halgren TA. Identifying and characterizing binding sites and assessing druggability. J. Chem. Inf. Model. 2009;49:377\u2013389. doi: 10.1021/ci800324m.", "ArticleIdList": ["10.1021/ci800324m", "19434839"]}, {"Citation": "Banko NS, et al. Glycogen synthase kinase 3\u03b1 deficiency attenuates atherosclerosis and hepatic steatosis in high fat diet-fed low density lipoprotein receptor-deficient mice. Am. J. Pathol. 2014;184:3394\u20133404. doi: 10.1016/j.ajpath.2014.07.028.", "ArticleIdList": ["10.1016/j.ajpath.2014.07.028", "25451156"]}, {"Citation": "Shahab L, Plattner F, Irvine EE, Cummings DM, Edwards FA. Dynamic range of GSK3\u03b1 not GSK3\u03b2 is essential for bidirectional synaptic plasticity at hippocampal CA3-CA1 synapses. Hippocampus. 2014;24:1413\u20131416. doi: 10.1002/hipo.22362.", "ArticleIdList": ["10.1002/hipo.22362", "PMC4258099", "25208523"]}, {"Citation": "Lanahan AA, et al. PTP1b is a physiologic regulator of vascular endothelial growth factor signaling in endothelial cells. Circulation. 2014;130:902\u2013909. doi: 10.1161/CIRCULATIONAHA.114.009683.", "ArticleIdList": ["10.1161/CIRCULATIONAHA.114.009683", "PMC6060619", "24982127"]}, {"Citation": "Zhou X, Xu W, Chen J. The 981\u2009C\u2009>\u2009T polymorphism in protein tyrosine phosphatase 1B is associated with decreased risk of coronary artery disease in Chinese Han population. Atherosclerosis. 2011;218:147\u2013150. doi: 10.1016/j.atherosclerosis.2011.05.021.", "ArticleIdList": ["10.1016/j.atherosclerosis.2011.05.021", "21676396"]}, {"Citation": "Ding-Zhou L, et al. LF 16-0687 Ms, a bradykinin B2 receptor antagonist, reduces ischemic brain injury in a murine model of transient focal cerebral ischemia. Br. J. Pharmacol. 2003;139:1539\u20131547. doi: 10.1038/sj.bjp.0705385.", "ArticleIdList": ["10.1038/sj.bjp.0705385", "PMC1573979", "12922942"]}, {"Citation": "Ferreira AP, et al. HOE-140, an antagonist of B2 receptor, protects against memory deficits and brain damage induced by moderate lateral fluid percussion injury in mice. Psychopharmacol. (Berl.) 2014;231:1935\u20131948. doi: 10.1007/s00213-013-3336-x.", "ArticleIdList": ["10.1007/s00213-013-3336-x", "24202114"]}, {"Citation": "Fang C, et al. Angiotensin 1\u20137 and Mas decrease thrombosis in Bdkrb2\u2212/\u2212 mice by increasing NO and prostacyclin to reduce platelet spreading and glycoprotein VI activation. Blood. 2013;121:3023\u20133032. doi: 10.1182/blood-2012-09-459156.", "ArticleIdList": ["10.1182/blood-2012-09-459156", "PMC3624945", "23386129"]}, {"Citation": "Huang X, et al. Role of tandospirone, a 5-HT1A receptor partial agonist, in the treatment of central nervous system disorders and the underlying mechanisms. Oncotarget. 2017;8:102705\u2013102720. doi: 10.18632/oncotarget.22170.", "ArticleIdList": ["10.18632/oncotarget.22170", "PMC5731992", "29254282"]}, {"Citation": "Hind. WH, England TJ, O\u2019Sullivan SE. Cannabidiol protects an in vitro model of the blood-brain barrier from oxygen-glucose deprivation via PPAR\u03b3 and 5-HT1A receptors. Br. J. Pharmacol. 2016;173:815\u2013825. doi: 10.1111/bph.13368.", "ArticleIdList": ["10.1111/bph.13368", "PMC4761095", "26497782"]}, {"Citation": "Pazos MR, Mohammed N, Lafuente H. Mechanisms of cannabidiol neuroprotection in hypoxic-ischemic newborn pigs: role of 5HT(1A) and CB2 receptors. Neuropharmacology. 2013;71:282\u2013291. doi: 10.1016/j.neuropharm.2013.03.027.", "ArticleIdList": ["10.1016/j.neuropharm.2013.03.027", "23587650"]}, {"Citation": "Cuartero MI, et al. The Kynurenine Pathway in the Acute and Chronic Phases of Cerebral Ischemia. Curr. Pharm. Des. 2016;22:1060\u20131073. doi: 10.2174/1381612822666151214125950.", "ArticleIdList": ["10.2174/1381612822666151214125950", "PMC4972938", "25248805"]}, {"Citation": "Mazarei G, et al. The absence of indoleamine 2,3-dioxygenase expression protects against NMDA receptor-mediated excitotoxicity in mouse brain. Exp. Neurol. 2013;249:144\u2013148. doi: 10.1016/j.expneurol.2013.08.007.", "ArticleIdList": ["10.1016/j.expneurol.2013.08.007", "23994717"]}, {"Citation": "Yeung AW, Terentis AC, King NJ, Thomas SR. Role of indoleamine 2,3-dioxygenase in health and disease. Clin. Sci. (Lond.) 2015;129:601\u2013672. doi: 10.1042/CS20140392.", "ArticleIdList": ["10.1042/CS20140392", "26186743"]}, {"Citation": "Kumar S, Ivanov S, Lagunin A, Goel RK. Glycogen synthase kinase-3 inhibition as a potential pharmacological target for vascular dementia: In silico and in vivo evidence. Comput. Biol. Med. 2019;108:305\u2013316. doi: 10.1016/j.compbiomed.2019.03.002.", "ArticleIdList": ["10.1016/j.compbiomed.2019.03.002", "31022582"]}, {"Citation": "Kumar S, Ivanov S, Lagunin A, Goel RK. Attenuation of hyperhomocysteinemia induced vascular dementia by sodium orthovanadate perhaps via PTP1B: Pertinent downstream outcomes. Behav. Brain Res. 2019;364:29\u201340. doi: 10.1016/j.bbr.2019.01.039.", "ArticleIdList": ["10.1016/j.bbr.2019.01.039", "30721761"]}, {"Citation": "Sibon I, et al. COL4A1 mutation in Axenfeld-Rieger anomaly with leukoencephalopathy and stroke. Ann. Neurol. 2007;62:177\u2013184. doi: 10.1002/ana.21191.", "ArticleIdList": ["10.1002/ana.21191", "17696175"]}, {"Citation": "Yoo JH, Choi GD, Kang SS. Pathogenicity of thermolabile methylenetetrahydrofolate reductase for vascular dementia. Arterioscler. Thromb. Vasc. Biol. 2000;20:1921\u20131925. doi: 10.1161/01.ATV.20.8.1921.", "ArticleIdList": ["10.1161/01.ATV.20.8.1921", "10938012"]}, {"Citation": "McIlroy SP, Dynan KB, Lawson JT, Patterson CC, Passmore AP. Moderately elevated plasma homocysteine, methylenetetrahydrofolate reductase genotype, and risk for stroke, vascular dementia, and Alzheimer disease in Northern Ireland. Stroke. 2002;33:2351\u20132356. doi: 10.1161/01.STR.0000032550.90046.38.", "ArticleIdList": ["10.1161/01.STR.0000032550.90046.38", "12364720"]}, {"Citation": "Jin P, et al. Association between MTHFR gene polymorphisms, smoking, and the incidence of vascular dementia. Asia. Pac. J. Public. Health. 2013;25(4 Suppl):57S\u201363S. doi: 10.1177/1010539513492819.", "ArticleIdList": ["10.1177/1010539513492819", "23858518"]}, {"Citation": "Malandrini A, et al. Asymptomatic cores and paracrystalline mitochondrial inclusions in CADASIL. Neurology. 2002;59:617\u2013620. doi: 10.1212/WNL.59.4.617.", "ArticleIdList": ["10.1212/WNL.59.4.617", "12196662"]}, {"Citation": "Utku U, Celik Y, Uyguner O, Y\u00fcksel-Apak M, Wollnik B. CADASIL syndrome in a large Turkish kindred caused by the R90C mutation in the Notch3 receptor. Eur. J. Neurol. 2002;9:23\u201328. doi: 10.1046/j.1468-1331.2002.00344.x.", "ArticleIdList": ["10.1046/j.1468-1331.2002.00344.x", "11784372"]}, {"Citation": "Ceroni M, et al. Migraine with aura and white matter abnormalities: Notch3 mutation. Neurology. 2000;54:1869\u20131871. doi: 10.1212/WNL.54.9.1869.", "ArticleIdList": ["10.1212/WNL.54.9.1869", "10802804"]}, {"Citation": "Liebetrau M, Herzog J, Kloss CU, Hamann GF, Dichgans M. Prolonged cerebral transit time in CADASIL: a transcranial ultrasound study. Stroke. 2002;3:509\u2013512. doi: 10.1161/hs0202.102949.", "ArticleIdList": ["10.1161/hs0202.102949", "11823661"]}, {"Citation": "Joutel A, et al. The ectodomain of the Notch3 receptor accumulates within the cerebrovasculature of CADASIL patients. J. Clin. Invest. 2000;105:597\u2013605. doi: 10.1172/JCI8047.", "ArticleIdList": ["10.1172/JCI8047", "PMC289174", "10712431"]}, {"Citation": "Dichgans M, Herzog J, Gasser T. NOTCH3 mutation involving three cysteine residues in a family with typical CADASIL. Neurology. 2001;57:1714\u20131717. doi: 10.1212/WNL.57.9.1714.", "ArticleIdList": ["10.1212/WNL.57.9.1714", "11706120"]}, {"Citation": "Tikka S, et al. CADASIL and CARASIL. Brain Pathol. 2014;24:525\u2013544. doi: 10.1111/bpa.12181.", "ArticleIdList": ["10.1111/bpa.12181", "PMC8029192", "25323668"]}, {"Citation": "Sato S, Mizukami K, Asada T. A preliminary open-label study of 5-HT1A partial agonist tandospirone for behavioural and psychological symptoms associated with dementia. Int. J. Neuropsychopharmacol. 2007;10:281\u2013283. doi: 10.1017/S1461145706007000.", "ArticleIdList": ["10.1017/S1461145706007000", "16817981"]}, {"Citation": "Moretti R, Torre P, Antonello RM, Cazzato G, Bava A. Rivastigmine in subcortical vascular dementia: an open 22-month study. J. Neurol. Sci. 2002;203\u2013204:141\u2013146. doi: 10.1016/S0022-510X(02)00280-0.", "ArticleIdList": ["10.1016/S0022-510X(02)00280-0", "12417373"]}, {"Citation": "Saletu B, Garg A, Shoeb A. Safety of nicergoline as an agent for management of cognitive function disorders. Biomed. Res. Int. 2014;2014:610103. doi: 10.1155/2014/610103.", "ArticleIdList": ["10.1155/2014/610103", "PMC4163411", "25243157"]}, {"Citation": "Sakr HF, et al. Effect of dehydroepiandrosterone (DHEA) on memory and brain derived neurotrophic factor (BDNF) in a rat model of vascular dementia. J. Physiol. Pharmacol. 2014;65:41\u201353.", "ArticleIdList": ["24622829"]}, {"Citation": "Li CJ, et al. Activation of GABAB receptors ameliorates cognitive impairment via restoring the balance of HCN1/HCN2 surface expression in the hippocampal CA1 area in rats with chronic cerebral hypoperfusion. Mol. Neurobiol. 2014;50:704\u2013720. doi: 10.1007/s12035-014-8736-3.", "ArticleIdList": ["10.1007/s12035-014-8736-3", "24838625"]}, {"Citation": "Kishi T, Hirooka Y, Sunagawa K. Telmisartan protects against cognitive decline via up-regulation of brain-derived neurotrophic factor/tropomyosin-related kinase B in hippocampus of hypertensive rats. J. Cardiol. 2012;60:489\u2013494. doi: 10.1016/j.jjcc.2012.08.004.", "ArticleIdList": ["10.1016/j.jjcc.2012.08.004", "22948091"]}, {"Citation": "Kaur J, Sharma S, Sandhu M, Sharma S. Neurokinin-1 receptor inhibition reverses ischaemic brain injury and dementia in bilateral common carotid artery occluded rats: possible mechanisms. Inflammopharmacology. 2016;24:133\u2013143. doi: 10.1007/s10787-016-0271-6.", "ArticleIdList": ["10.1007/s10787-016-0271-6", "27380492"]}, {"Citation": "Iwanami J, et al. Direct angiotensin II type 2 receptor stimulation by compound 21 prevents vascular dementia. J. Am. Soc. Hypertens. 2015;9:250\u2013256. doi: 10.1016/j.jash.2015.01.010.", "ArticleIdList": ["10.1016/j.jash.2015.01.010", "25753301"]}, {"Citation": "Gupta S, Sharma B, Singh P, Sharma BM. Modulation of transient receptor potential vanilloid subtype 1 (TRPV1) and norepinephrine transporters (NET) protect against oxidative stress, cellular injury, and vascular dementia. Curr. Neurovasc Res. 2014;11:94\u2013106. doi: 10.2174/1567202611666140305221854.", "ArticleIdList": ["10.2174/1567202611666140305221854", "24597602"]}, {"Citation": "Cuartero MI, et al. L-kynurenine/aryl hydrocarbon receptor pathway mediates brain damage after experimental stroke. Circulation. 2014;130:2040\u20132051. doi: 10.1161/CIRCULATIONAHA.114.011394.", "ArticleIdList": ["10.1161/CIRCULATIONAHA.114.011394", "25359166"]}, {"Citation": "Peeters-Scholte C, et al. Neuroprotection by selective nitric oxide synthase inhibition at 24\u2009h after perinatal hypoxia-ischemia. Stroke. 2002;33:2304\u20132310. doi: 10.1161/01.STR.0000028343.25901.09.", "ArticleIdList": ["10.1161/01.STR.0000028343.25901.09", "12215603"]}, {"Citation": "Garry PS, Ezra M, Rowland MJ, Westbrook J, Pattinson KT. The role of the nitric oxide pathway in brain injury and its treatment\u2013from bench to bedside. Exp. Neurol. 2015;263:235\u2013243. doi: 10.1016/j.expneurol.2014.10.017.", "ArticleIdList": ["10.1016/j.expneurol.2014.10.017", "25447937"]}, {"Citation": "Vitcheva V, Simeonova R, Kondeva-Burdina M, Mitcheva M. Selective Nitric Oxide Synthase Inhibitor 7-Nitroindazole Protects against Cocaine-Induced Oxidative Stress in Rat Brain. Oxid. Med. Cell Longev. 2015;2015:157876. doi: 10.1155/2015/157876.", "ArticleIdList": ["10.1155/2015/157876", "PMC4630414", "26576217"]}, {"Citation": "Harkin AJ, Bruce KH, Craft B, Paul IA. Nitric oxide synthase inhibitors have antidepressant-like properties in mice. 1. Acute treatments are active in the forced swim test. Eur. J. Pharmacol. 1999;372:207\u2013213. doi: 10.1016/S0014-2999(99)00191-0.", "ArticleIdList": ["10.1016/S0014-2999(99)00191-0", "10395013"]}, {"Citation": "Sevgi S, Ozek M, Eroglu L. L-NAME prevents anxiety-like and depression-like behavior in rats exposed to restraint stress. Methods Find. Exp. Clin. Pharmacol. 2006;28:95\u201399. doi: 10.1358/mf.2006.28.2.977840.", "ArticleIdList": ["10.1358/mf.2006.28.2.977840", "16636719"]}, {"Citation": "Kanzariya NR, Patel RK, Patel NJ. Antidiabetic and vasoprotective activity of lithium: Role of glycogen synthase kinase-3. Indian. J. Pharmacol. 2011;43:433\u2013436. doi: 10.4103/0253-7613.83116.", "ArticleIdList": ["10.4103/0253-7613.83116", "PMC3153708", "21845000"]}, {"Citation": "Avila. J, Wandosell F, Hern\u00e1ndez F. Role of glycogen synthase kinase-3 in Alzheimer\u2019s disease pathogenesis and glycogen synthase kinase-3 inhibitors. Expert. Rev. Neurother. 2010;10:703\u2013710. doi: 10.1586/ern.10.40.", "ArticleIdList": ["10.1586/ern.10.40", "20420491"]}, {"Citation": "Li X, Liu M, Cai Z, Wang G, Li X. Regulation of glycogen synthase kinase-3 during bipolar mania treatment. Bipolar Disord. 2010;12:741\u2013752. doi: 10.1111/j.1399-5618.2010.00866.x.", "ArticleIdList": ["10.1111/j.1399-5618.2010.00866.x", "PMC3059222", "21040291"]}, {"Citation": "Gould TD, Chen G, Manji HK. In vivo evidence in the brain for lithium inhibition of glycogen synthase kinase-3. Neuropsychopharmacology. 2004;29:32\u201338. doi: 10.1038/sj.npp.1300283.", "ArticleIdList": ["10.1038/sj.npp.1300283", "12942141"]}, {"Citation": "Kaplanski J, et al. LF 16-0687 Ms, a bradykinin B2 receptor antagonist, reduces brain edema and improves long-term neurological function recovery after closed head trauma in rats. J. Neurotrauma. 2002;19:953\u2013964. doi: 10.1089/089771502320317104.", "ArticleIdList": ["10.1089/089771502320317104", "12225655"]}, {"Citation": "Bartal C, Zeldetz V, Stavi V, Barski L. The role of icatibant-the B2 bradykinin receptor antagonist-in life-threatening laryngeal angioedema in the ED. Am. J. Emerg. Med. 2015;33(3):479.e1\u20133. doi: 10.1016/j.ajem.2014.08.055.", "ArticleIdList": ["10.1016/j.ajem.2014.08.055", "25241359"]}, {"Citation": "Terzuoli E, et al. Antagonism of bradykinin B2 receptor prevents inflammatory responses in human endothelial cells by quenching the NF-kB pathway activation. PLoS One. 2014;9:e84358. doi: 10.1371/journal.pone.0084358;.", "ArticleIdList": ["10.1371/journal.pone.0084358;", "PMC3879294", "24392129"]}, {"Citation": "Kim JY, Kim N, Yenari MA, Chang W. Hypothermia and pharmacological regimens that prevent overexpression and overactivity of the extracellular calcium-sensing receptor protect neurons against traumatic brain injury. J. Neurotrauma. 2013;30:1170\u20131176. doi: 10.1089/neu.2012.2691.", "ArticleIdList": ["10.1089/neu.2012.2691", "PMC3700438", "23360235"]}, {"Citation": "Kim JY, et al. Calcium-sensing receptor (CaSR) as a novel target for ischemic neuroprotection. Ann. Clin. Transl. Neurol. 2014;1:851\u2013866. doi: 10.1002/acn3.118.", "ArticleIdList": ["10.1002/acn3.118", "PMC4265057", "25540800"]}, {"Citation": "Kobayashi-Torii M, et al. Possible participation of extracellular calcium-sensing receptor in blood pressure regulation in rats. Brain Res. 2011;1367:181\u2013187. doi: 10.1016/j.brainres.2010.10.013.", "ArticleIdList": ["10.1016/j.brainres.2010.10.013", "20940004"]}, {"Citation": "Schepelmann M, et al. The vascular Ca2\u2009+\u2009-sensing receptor regulates blood vessel tone and blood pressure. Am. J. Physiol. Cell Physiol. 2016;310:C193\u2013204. doi: 10.1152/ajpcell.00248.2015.", "ArticleIdList": ["10.1152/ajpcell.00248.2015", "PMC5243220", "26538090"]}, {"Citation": "Bandyopadhyay S, Tfelt-Hansen J, Chattopadhyay N. Diverse roles of extracellular calcium-sensing receptor in the central nervous system. J. Neurosci. Res. 2010;88:2073\u20132082. doi: 10.1002/jnr.22391.", "ArticleIdList": ["10.1002/jnr.22391", "20336672"]}, {"Citation": "Gazarini L, Stern CA, Carobrez AP, Bertoglio LJ. Enhanced noradrenergic activity potentiates fear memory consolidation and reconsolidation by differentially recruiting \u03b11- and \u03b2-adrenergic receptors. Learn. Mem. 2013;20(4):210\u2013219. doi: 10.1101/lm.030007.112.", "ArticleIdList": ["10.1101/lm.030007.112", "23512937"]}, {"Citation": "Torkaman-Boutorabi A, Danyali F, Oryan S, Ebrahimi-Ghiri M, Zarrindast MR. Hippocampal \u03b1-adrenoceptors involve in the effect of histamine on spatial learning. Physiol. Behav. 2014;129:17\u201324. doi: 10.1016/j.physbeh.2014.02.009.", "ArticleIdList": ["10.1016/j.physbeh.2014.02.009", "24534171"]}, {"Citation": "Haapalinna A, Sirvi\u00f6 J, MacDonald E, Virtanen R, Heinonen E. The effects of a specific alpha(2)-adrenoceptor antagonist, atipamezole, on cognitive performance and brain neurochemistry in aged Fisher 344 rats. Eur. J. Pharmacol. 2000;387:141\u2013150. doi: 10.1016/S0014-2999(99)00819-5.", "ArticleIdList": ["10.1016/S0014-2999(99)00819-5", "10650154"]}, {"Citation": "Veyrac A, Nguyen V, Marien M, Didier A, Jourdan F. Noradrenergic control of odor recognition in a nonassociative olfactory learning task in the mouse. Learn. Mem. 2007;14:847\u2013854. doi: 10.1101/lm.708807.", "ArticleIdList": ["10.1101/lm.708807", "PMC2151022", "18086828"]}, {"Citation": "Chopin P, Colpaert FC, Marien M. Effects of acute and subchronic administration of dexefaroxan, an alpha(2)-adrenoceptor antagonist, on memory performance in young adult and aged rodents. J. Pharmacol. Exp. Ther. 2002;301:187\u2013196. doi: 10.1124/jpet.301.1.187.", "ArticleIdList": ["10.1124/jpet.301.1.187", "11907173"]}, {"Citation": "Camacho F, Smith CP, Vargas HM, Winslow JT. Alpha 2-adrenoceptor antagonists potentiate acetylcholinesterase inhibitor effects on passive avoidance learning in the rat. Psychopharmacol. (Berl.) 1996;124:347\u2013354. doi: 10.1007/BF02247440.", "ArticleIdList": ["10.1007/BF02247440", "8739550"]}, {"Citation": "Haddjeri N, Blier P, de Montigny C. Effects of long-term treatment with the alpha 2-adrenoceptor antagonist mirtazapine on 5-HT neurotransmission. Naunyn Schmiedebergs Arch. Pharmacol. 1997;355:20\u201329. doi: 10.1007/PL00004913.", "ArticleIdList": ["10.1007/PL00004913", "9007838"]}, {"Citation": "Kashiwagi A, et al. New alpha 2-adrenergic blocker (DG-5128) improves insulin secretion and in vivo glucose disposal in NIDDM patients. Diabetes. 1986;35:1085\u20131089. doi: 10.2337/diab.35.10.1085.", "ArticleIdList": ["10.2337/diab.35.10.1085", "2875910"]}, {"Citation": "Abdel-Zaher AO, Ahmed IT, El-Koussi AD. The potential antidiabetic activity of some alpha-2 adrenoceptor antagonists. Pharmacol. Res. 2001;44:397\u2013409. doi: 10.1006/phrs.2001.0870.", "ArticleIdList": ["10.1006/phrs.2001.0870", "11712871"]}, {"Citation": "Fagerholm V, Haaparanta M, Scheinin M. \u03b12-adrenoceptor regulation of blood glucose homeostasis. Basic. Clin. Pharmacol. Toxicol. 2011;108:365\u2013370. doi: 10.1111/j.1742-7843.2011.00699.x.", "ArticleIdList": ["10.1111/j.1742-7843.2011.00699.x", "21418144"]}, {"Citation": "Chopin P, Colpaert FC, Marien M. Effects of alpha-2 adrenoceptor agonists and antagonists on circling behavior in rats with unilateral 6-hydroxydopamine lesions of the nigrostriatal pathway. J. Pharmacol. Exp. Ther. 1999;288:798\u2013804.", "ArticleIdList": ["9918591"]}, {"Citation": "Lahousse SA, Stopa EG, Mulberg AE, de la Monte SM. Reduced expression of the cystic fibrosis transmembrane conductance regulator gene in the hypothalamus of patients with Alzheimer\u2019s disease. J. Alzheimers Dis. 2003;5:455\u2013462. doi: 10.3233/JAD-2003-5605.", "ArticleIdList": ["10.3233/JAD-2003-5605", "14757935"]}, {"Citation": "Uramoto H, Okada T, Okada Y. Protective role of cardiac CFTR activation upon early reperfusion against myocardial infarction. Cell Physiol. Biochem. 2012;30:1023\u20131038. doi: 10.1159/000341479.", "ArticleIdList": ["10.1159/000341479", "23221371"]}, {"Citation": "Guo Y, Su M, McNutt MA, Gu J. Expression and distribution of cystic fibrosis transmembrane conductance regulator in neurons of the human brain. J. Histochem. Cytochem. 2009;57:1113\u20131120. doi: 10.1369/jhc.2009.953455.", "ArticleIdList": ["10.1369/jhc.2009.953455", "PMC2778084", "19654104"]}, {"Citation": "Tsabari R, et al. CFTR potentiator therapy ameliorates impaired insulin secretion in CF patients with a gating mutation. J. Cyst. Fibros. 2016;15:e25\u201327. doi: 10.1016/j.jcf.2015.10.012.", "ArticleIdList": ["10.1016/j.jcf.2015.10.012", "26547591"]}, {"Citation": "Gong X, et al. Down-regulation of IGF-1/IGF-1R in hippocampus of rats with vascular dementia. Neurosci. Lett. 2012;513:20\u201324. doi: 10.1016/j.neulet.2012.01.077.", "ArticleIdList": ["10.1016/j.neulet.2012.01.077", "22342912"]}, {"Citation": "Wang J, et al. Insulin-like growth factor-1 secreted by brain microvascular endothelial cells attenuates neuron injury upon ischemia. FEBS J. 2013;280:3658\u20133668. doi: 10.1111/febs.12359.", "ArticleIdList": ["10.1111/febs.12359", "23721666"]}, {"Citation": "Chang HC, Yang YR, Wang PS, Kuo CH, Wang RY. The neuroprotective effects of intramuscular insulin-like growth factor-I treatment in brain ischemic rats. PLoS One. 2013;8:e64015. doi: 10.1371/journal.pone.0064015.", "ArticleIdList": ["10.1371/journal.pone.0064015", "PMC3661564", "23717526"]}, {"Citation": "Gao S, et al. MicroRNA-133a regulates insulin-like growth factor-1 receptor expression and vascular smooth muscle cell proliferation in murine atherosclerosis. Atherosclerosis. 2014;232:171\u2013179. doi: 10.1016/j.atherosclerosis.2013.11.029.", "ArticleIdList": ["10.1016/j.atherosclerosis.2013.11.029", "PMC4334121", "24401233"]}, {"Citation": "Higashi Y, et al. Insulin-Like Growth Factor-1 Receptor Deficiency in Macrophages Accelerates Atherosclerosis and Induces an Unstable Plaque Phenotype in Apolipoprotein E-Deficient Mice. Circulation. 2016;133:2263\u20132278. doi: 10.1161/CIRCULATIONAHA.116.021805.", "ArticleIdList": ["10.1161/CIRCULATIONAHA.116.021805", "PMC4899151", "27154724"]}, {"Citation": "Higashi Y, et al. Interaction between insulin-like growth factor-1 and atherosclerosis and vascular aging. Front. Horm. Res. 2014;43:107\u2013124.", "ArticleIdList": ["PMC4199335", "24943302"]}, {"Citation": "Cheng J, et al. Insulin-like growth factor-1 receptor polymorphism and ischemic stroke: a case-control study in Chinese population. Acta Neurol. Scand. 2008;118:333\u2013338. doi: 10.1111/j.1600-0404.2008.01040.x.", "ArticleIdList": ["10.1111/j.1600-0404.2008.01040.x", "18477064"]}, {"Citation": "Clemmons DR. Modifying IGF1 activity: an approach to treat endocrine disorders, atherosclerosis and cancer. Nat. Rev. Drug. Discov. 2007;6:821\u2013833. doi: 10.1038/nrd2359.", "ArticleIdList": ["10.1038/nrd2359", "17906644"]}, {"Citation": "Cheng PW, et al. Tseng. Involvement of two distinct signalling pathways in IGF-1-mediated central control of hypotensive effects in normotensive and hypertensive rats. Acta Physiol. (Oxf). 2014;212:28\u201338. doi: 10.1111/apha.12340.", "ArticleIdList": ["10.1111/apha.12340", "24995704"]}, {"Citation": "Raber J. AR, apoE, and cognitive function. Horm. Behav. 2008;53:706\u2013715. doi: 10.1016/j.yhbeh.2008.02.012.", "ArticleIdList": ["10.1016/j.yhbeh.2008.02.012", "PMC2409114", "18395206"]}, {"Citation": "Pike CJ, Carroll JC, Rosario ER, Barron AM. Protective actions of sex steroid hormones in Alzheimer\u2019s disease. Front. Neuroendocrinol. 2009;30:239\u2013258. doi: 10.1016/j.yfrne.2009.04.015.", "ArticleIdList": ["10.1016/j.yfrne.2009.04.015", "PMC2728624", "19427328"]}, {"Citation": "Pal M, Gupta S. Testosterone supplementation improves glucose homeostasis despite increasing hepatic insulin resistance in male mouse model of type 2 diabetes mellitus. Nutr. Diabetes. 2016;6:e236. doi: 10.1038/nutd.2016.45.", "ArticleIdList": ["10.1038/nutd.2016.45", "PMC5223134", "27941939"]}, {"Citation": "Uchida M, et al. Dose-dependent effects of androgens on outcome after focal cerebral ischemia in adult male mice. J. Cereb. Blood Flow. Metab. 2009;29:1454\u20131462. doi: 10.1038/jcbfm.2009.60.", "ArticleIdList": ["10.1038/jcbfm.2009.60", "PMC2821811", "19436313"]}, {"Citation": "Zhang W, et al. Effects of androgens on early post-ischemic neurogenesis in mice. Transl. Stroke Res. 2014;5:301\u2013311. doi: 10.1007/s12975-013-0298-6.", "ArticleIdList": ["10.1007/s12975-013-0298-6", "24323721"]}, {"Citation": "Cheng J, et al. Age-dependent effects of testosterone in experimental stroke. J. Cereb. Blood Flow. Metab. 2009;29:486\u2013494. doi: 10.1038/jcbfm.2008.138.", "ArticleIdList": ["10.1038/jcbfm.2008.138", "PMC2843561", "19002196"]}, {"Citation": "Huang CK, et al. New therapy via targeting androgen receptor in monocytes/macrophages to battle atherosclerosis. Hypertension. 2014;63:1345\u20131353. doi: 10.1161/HYPERTENSIONAHA.113.02804.", "ArticleIdList": ["10.1161/HYPERTENSIONAHA.113.02804", "PMC4080890", "24688120"]}, {"Citation": "Fagman JB, et al. The androgen receptor confers protection against diet-induced atherosclerosis, obesity, and dyslipidemia in female mice. FASEB J. 2015;29:1540\u20131550. doi: 10.1096/fj.14-259234.", "ArticleIdList": ["10.1096/fj.14-259234", "PMC4470404", "25550469"]}, {"Citation": "Chignalia AZ, et al. Testosterone induces vascular smooth muscle cell migration by NADPH oxidase and c-Src-dependent pathways. Hypertension. 2012;59:1263\u20131271. doi: 10.1161/HYPERTENSIONAHA.111.180620.", "ArticleIdList": ["10.1161/HYPERTENSIONAHA.111.180620", "22566500"]}, {"Citation": "Chang C, Yeh S, Lee SO, Chang TM. Androgen receptor (AR) pathophysiological roles in androgen-related diseases in skin, bone/muscle, metabolic syndrome and neuron/immune systems: lessons learned from mice lacking AR in specific cells. Nucl. Recept. Signal. 2013;11:e001. doi: 10.1621/nrs.11001.", "ArticleIdList": ["10.1621/nrs.11001", "PMC3960937", "24653668"]}, {"Citation": "Navarro G, et al. Extranuclear Actions of the Androgen Receptor Enhance Glucose-Stimulated Insulin Secretion in the Male. Cell Metab. 2016;23:837\u2013851. doi: 10.1016/j.cmet.2016.03.015.", "ArticleIdList": ["10.1016/j.cmet.2016.03.015", "PMC4864089", "27133133"]}, {"Citation": "Yoshida S, et al. Androgen receptor promotes sex-independent angiogenesis in response to ischemia and is required for activation of vascular endothelial growth factor receptor signaling. Circulation. 2013;128:60\u201371. doi: 10.1161/CIRCULATIONAHA.113.001533.", "ArticleIdList": ["10.1161/CIRCULATIONAHA.113.001533", "PMC3933182", "23723256"]}, {"Citation": "Venna VR, Benashski SE, Chauhan A, McCullough LD. Inhibition of glycogen synthase kinase-3\u03b2 enhances cognitive recovery after stroke: the role of TAK1. Learn. Mem. 2015;22:336\u2013343. doi: 10.1101/lm.038083.115.", "ArticleIdList": ["10.1101/lm.038083.115", "PMC4478333", "26077686"]}, {"Citation": "Thareja S, Aggarwal S, Bhardwaj TR, Kumar M. Protein tyrosine phosphatase 1B inhibitors: a molecular level legitimate approach for the management of diabetes mellitus. Med. Res. Rev. 2012;32:459\u2013517. doi: 10.1002/med.20219.", "ArticleIdList": ["10.1002/med.20219", "20814956"]}, {"Citation": "Hassid A, Huang S, Yao J. Role of PTP-1B in aortic smooth muscle cell motility and tyrosine phosphorylation of focal adhesion proteins. Am. J. Physiol. 1999;277:H192\u2013H198.", "ArticleIdList": ["10409197"]}, {"Citation": "Bruder-Nascimento T, et al. Deletion of protein tyrosine phosphatase 1b in proopiomelanocortin neurons reduces neurogenic control of blood pressure and protects mice from leptin- and sympatho-mediated hypertension. Pharmacol. Res. 2015;102:235\u2013244. doi: 10.1016/j.phrs.2015.10.012.", "ArticleIdList": ["10.1016/j.phrs.2015.10.012", "26523876"]}, {"Citation": "Belin de CEJ, et al. Protein tyrosine phosphatase 1B, a major regulator of leptin-mediated control of cardiovascular function. Circulation. 2009;120:753\u2013763. doi: 10.1161/CIRCULATIONAHA.109.853077.", "ArticleIdList": ["10.1161/CIRCULATIONAHA.109.853077", "PMC2736363", "19687357"]}]}], "History": [{"Year": "2019", "Month": "8", "Day": "2"}, {"Year": "2019", "Month": "12", "Day": "21"}, {"Year": "2020", "Month": "1", "Day": "16", "Hour": "6", "Minute": "0"}, {"Year": "2020", "Month": "1", "Day": "16", "Hour": "6", "Minute": "0"}, {"Year": "2020", "Month": "11", "Day": "11", "Hour": "6", "Minute": "0"}, {"Year": "2020", "Month": "1", "Day": "14"}], "PublicationStatus": "epublish", "ArticleIdList": ["31937840", "PMC6959222", "10.1038/s41598-019-57199-9", "10.1038/s41598-019-57199-9"]}}]}